Why the study?
Does thrombolytic therapy with streptokinase reduce in-hospital death and provide cost-effective treatment in patients 75 years of age or older with suspected acute myocardial infarction?
Does thrombolytic therapy with streptokinase reduce in-hospital death and provide cost-effective treatment in patients 75 years of age or older with suspected acute myocardial infarction?
Thrombolytic therapy with streptokinase is projected to be a beneficial and cost-effective treatment for suspected acute myocardial infarction in elderly patients.
No takes yet. Share an insight, caveat, or question.
Supports cost-effectiveness of thrombolysis in elderly AMI; leaves open prospective validation in contemporary practice.
Krumholz et al. (1992) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: